Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Net (2021 - 2025)

Historic Receivables - Net for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to $72.6 million.

  • Tarsus Pharmaceuticals' Receivables - Net rose 14904.83% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.6 million, marking a year-over-year increase of 14904.83%. This contributed to the annual value of $46.8 million for FY2024, which is 18133.08% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Receivables - Net stood at $72.6 million, which was up 14904.83% from $58.3 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Receivables - Net registered a high of $72.6 million during Q3 2025, and its lowest value of $17000.0 during Q1 2022.
  • Its 5-year average for Receivables - Net is $26.5 million, with a median of $25.0 million in 2021.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 9993.2% in 2022, then skyrocketed by 3144117.65% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Receivables - Net (Quarter) stood at $20.0 million in 2021, then tumbled by 99.92% to $17000.0 in 2022, then skyrocketed by 97670.59% to $16.6 million in 2023, then surged by 181.33% to $46.8 million in 2024, then soared by 55.3% to $72.6 million in 2025.
  • Its Receivables - Net was $72.6 million in Q3 2025, compared to $58.3 million in Q2 2025 and $62.4 million in Q1 2025.